Research programme: annexin therapeutics - Unigene Laboratories

Drug Profile

Research programme: annexin therapeutics - Unigene Laboratories

Alternative Names: Annexin peptides

Latest Information Update: 19 Jan 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Unigene Laboratories; University of London
  • Class Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Cardiovascular disorders; Inflammation; Reperfusion injury

Highest Development Phases

  • Suspended Cardiovascular disorders; Inflammation; Reperfusion injury

Most Recent Events

  • 11 Jan 2011 Unigene Laboratories' annexin therapeutics programme is available for licensing. http://www.unigene.com
  • 11 Aug 2007 Preclinical trials in Reperfusion injuries, Cardiovascular disorders, and Inflammation in United Kingdom (unspecified route)
  • 11 Aug 2007 Preclinical trials in Reperfusion injuries, Cardiovascular disorders, and Inflammation in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top